Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide versus darunavir/cobicistat plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1 infection
2015-000754-38Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Human immunodeficiency virus infection type 1 comparing D/C/F/TAF single-tablet regimen with DRV/COBI plus FTC/TDF (2 arms). Primary endpoint: Percentage of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot Approach at Week 48. Started Jun 2015; status: completed.
02
Drugs
darunavircobicistatemtricitabinetenofovir alafenamidetenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2015-000754-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000754-38.